- Home
- ARVN
ARVN
Arvinas Inc.
as 06-05-2025 4:00pm EST
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 456.2M | IPO Year: | 2018 |
| Target Price: | $20.53 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.90 - $34.11 | Next Earning Date: | 07-29-2025 |
| Revenue: | $426,900,000 | Revenue Growth: | 498.74% |
| Revenue Growth (this year): | 2.83% | Revenue Growth (next year): | -46.51% |
Stock Insider Trading Activity of Arvinas Inc. (ARVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Berkowitz Noah | ARVN | Chief Medical Officer | Mar 18 '25 | Sell | $8.59 | 8,658 | $74,372.22 | 110,023 |
Latest Arvinas Inc. News
ARVN Breaking Stock News: Dive into ARVN Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 hours ago
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting
MT Newswires
3 days ago
Arvinas, Pfizer Report Breast Cancer Treatment Phase 3 Trial Results; Arvinas Shares Down Pre-Bell
GlobeNewswire
5 days ago
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
BioPharma Dive
6 days ago
Full Arvinas, Pfizer data confirm potential, limits of ‘Protac’ drug in breast cancer
Zacks
6 days ago
Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect?
GlobeNewswire
6 days ago
Arvinas to Present at Jefferies Global Healthcare Conference
Clinical Trials Arena
7 days ago
Pfizer and Arvinas gamble to shift breast cancer treatment paradigm
MT Newswires
21 days ago
UBS Adjusts Price Target on Arvinas to $21 From $74, Maintains Buy Rating
Compare ARVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARVN Arvinas Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.